Avanir prevails in patent case

The U.S. District Court for the District of Delaware rules in favor of Avanir Pharmaceuticals (AVNR+1.5%) in its patent infringement case against Par Pharmaceuticals and Impax Laboratories (IPXL-1.3%) regarding their ANDAs for generic versions of Nuedexta.

The judge upheld the validity of patents '282 and '484 and ruled the proposed formulations infringe on both of them.

Nuedexta is the only FDA-approved product for the treatment of pseudobulbar effect. Based on the court's decision, the product has 12 years of market exclusivity remaining.